What Women Are Still Getting Wrong About Hormone Therapy in 2026
Last updated: April, 2026
Something shifted in women's health this past November, and most women have not heard about it yet. On November 10, 2025, the FDA removed the black box warning from menopausal hormone therapy medications. That warning had been attached to these treatments for more than two decades, and its removal was not a bureaucratic housekeeping move. It was a formal acknowledgment that the evidence had changed, and that the fear-based messaging surrounding hormone therapy had caused real harm.
Women who could have benefited from treatment spent years suffering through sleepless nights, debilitating hot flashes, and accelerating bone loss because a flawed study generated lasting panic. That study, the Women's Health Initiative, enrolled women with an average age of 63 years old, a full decade older than when most women enter menopause. The risk profile for a 63-year-old starting hormone therapy looks very different from that of a 50-year-old. The original data was real. Its interpretation and application were not.
In my practice, I see the consequences of that misapplication regularly. Women who have been told for years that hormone therapy is dangerous come in with symptoms that are measurably affecting their health, their sleep, their cognition, and their relationships. Many of them have never had an honest conversation about what the actual numbers look like.
That is what this piece is for.
The Breast Cancer Numbers Women Deserve to Know
The fear of breast cancer is the reason most women avoid hormone therapy entirely. It is also one of the most distorted statistics in all of medicine.
For women between the ages of 50 and 79, the baseline incidence of breast cancer without any hormone therapy is approximately 600 cases per 10,000 women. Among women who take combined estrogen-progestin therapy, that number rises to approximately 608 cases per 10,000 women. The absolute increase is eight cases per 10,000 women.
That is the number that should have anchored public conversation for the past two decades. It rarely did.
The picture shifts further when you look at women who have had a hysterectomy and take estrogen alone. In that group, the data suggests a decreased risk of breast cancer compared to women taking no hormone therapy at all. This is not a footnote. It is a central finding that was consistently underreported.
None of this means hormone therapy is appropriate for every woman. There are individual health histories, family histories, and risk factors that absolutely belong in the conversation. But a woman who has been told she cannot consider hormone therapy because it causes breast cancer, without any discussion of the actual numbers, has not had a full conversation.
Why Timing Changes Everything
One of the most important advances in menopause medicine over the past fifteen years is the concept of the treatment window. The body's relationship to estrogen is not static, and the timing of when hormone therapy begins affects both its risk profile and its benefits.
Women who start hormone therapy before age 60 or within ten years of menopause onset face significantly lower cardiovascular risks than those who begin therapy much later. Estrogen receptors in the cardiovascular system are more responsive earlier in the menopause transition. Introducing estrogen into an arterial environment that has already undergone significant aging without it produces different effects than maintaining hormonal support through the early transition years.
The delivery method also matters. Non-oral estrogen, including transdermal patches and gels, bypasses first-pass liver metabolism and carries a lower risk of blood clots than oral formulations. These are meaningful distinctions that should inform individualized treatment decisions, but they rarely come up in standard fifteen-minute appointments.
In a concierge medicine setting, they do.
Risk Is Not One-Size-Fits-All
One of the most persistent and damaging myths about hormone therapy is that all women face the same risks. They do not. Risk varies by age, by proximity to menopause onset, by the type of hormones used, by the route of administration, and by each woman's individual health history.
Most healthy women under the age of 60 who are within ten years of their final menstrual period can use hormone therapy safely to address moderate to severe vasomotor symptoms. The categorical warnings that were common a decade ago are inconsistent with current evidence or guidance from The Menopause Society.
This is why individualized assessment matters. When I evaluate a patient for hormone therapy, I am looking at her full picture: her symptom severity, her family history, her cardiovascular baseline, her bone density trajectory, and her own goals for treatment. That evaluation takes time. It cannot happen in a rushed appointment, and it cannot be reduced to a single risk category.
The Case for Vaginal Estrogen
Genitourinary syndrome of menopause, which includes vaginal dryness, recurrent urinary tract infections, discomfort during intercourse, and urinary urgency, is one of the most undertreated conditions in women's health. Unlike hot flashes, which often improve on their own over time, genitourinary symptoms tend to worsen without treatment.
Low-dose vaginal estrogen is highly effective for these symptoms and carries minimal systemic absorption. The risks associated with systemic hormone therapy do not apply in the same way to localized vaginal treatment. For years, the black box warning on hormone therapy products created confusion about this distinction. Women and their providers treated vaginal estrogen as if it carried the same concerns as systemic therapy. It does not.
Women who are not candidates for systemic therapy may still be excellent candidates for vaginal estrogen. This distinction matters enormously for quality of life, and it is one that often gets lost in brief clinical conversations.
What Hormone Therapy Actually Treats
Hot flashes and night sweats are the most discussed indications for hormone therapy, but they represent only part of what treatment addresses.
Bone density is a significant concern for postmenopausal women. Estrogen plays a direct role in bone maintenance, and the years immediately following menopause are often when the most rapid bone loss occurs. Hormone therapy has well-established protective effects on bone, reducing the risk of fractures in women who are appropriate candidates.
There is also emerging research on cognitive effects. Some studies have found a meaningful reduction in dementia risk among women who begin hormone therapy early in the menopause transition. This research is still evolving, and I am careful not to overstate it. But it is another reason why the timing of treatment initiation deserves more attention than it typically receives.
The quality-of-life benefits, improved sleep, mood stability, relief from vasomotor symptoms, and resolution of genitourinary discomfort are substantial and well documented. For women with moderate-to-severe symptoms, these are not minor quality-of-life adjustments. They represent meaningful changes to daily functioning, relationships, and long-term health.
How to Have the Conversation Your Health Deserves
The removal of the black box warning is a marker of how far the evidence has moved. But regulatory changes do not automatically translate into better clinical conversations. Women are still walking into appointments where hormone therapy is dismissed without a complete discussion of the actual data, or where the conversation never happens at all.
If you are experiencing menopausal symptoms that are affecting your sleep, your cognition, your mood, or your physical comfort, that experience deserves a full conversation. Not a brief reassurance that your symptoms are normal, or a referral to a handout about lifestyle changes. A real conversation, grounded in your specific health history and current evidence, about what treatment options actually exist and what the real numbers look like for someone like you.
That is the kind of care I provide at Concierge Medicine of Westlake. The concierge model exists precisely because these conversations take time. Extended appointments, direct access, and continuity of care make it possible to do menopause medicine correctly: individualized, evidence-based, and without the pressure of a waiting room full of patients behind you.
For women who are not candidates for hormone therapy, the conversation is equally important. There are newer non-hormonal medications that have shown real efficacy for vasomotor symptoms, and those options deserve the same careful discussion.
If you are ready to have that conversation, you can reach Concierge Medicine of Westlake at 440-797-1871 or visit conciergemedicineofwestlake.com
